Abstract：Objective：To observe the clinical effect of Chaishao Liujunzi Decoction combined with Jiedu Huaxian Adhesive Plaster for hepatic fibrosis in chronic hepatitis B. Methods：A total of 60 cases of patients with hepatic fibrosis in chronic hepatitis B were divided into the control group and the observation group according to the random number table method，with 30 cases in each group. The control group was given the oral administration of Entecavir Dispersible Tablets，and the observation group was additionally treated with the oral administration of Chaishao Liujunzi Decoction and the point application with Jiedu Huaxian Adhesive Plaster based on the treatment of the control group. Both groups were treated for six months. The changes in the levels of liver fibrosis indexes [type Ⅲ procollagen (PC Ⅲ)， laminin (LN)， type Ⅳ collage Ⅳ- C ( Ⅳ- C)， hyaluronic acid (HA)]， liver stiffness measurement (LSM)， liver function [alanine transaminase (ALT)，aspartate transaminase (AST)，total bilirubin (TBil)，gamma- glutamyl transpeptidase (GGT)] before and after treatment，and the curative effects of traditional Chinese medicine syndromes were compared between the two groups. Results： The total effective rate was 86.67% in the observation group， higher than that of 60.00% in the control group， the difference being significant (P＜0.05). After treatment， the levels of PC Ⅲ， LN， Ⅳ- C， and HA， and the values of LSM in the two groups were decreased when compared with those before treatment (P＜0.05)，and the decrease in the above levels in the observation group was more significant than that in the control group (P＜0.05). After treatment，the levels of ALT， AST， TBil， and GGT in serum in the two groups were decreased when compared with those before treatment (P＜0.05)， and the decrease in the above indexes in the observation group was more significant than that in the control group (P＜0.05). Conclusion： Chaishao Liujunzi Decoction combined with Jiedu Huaxian Adhesive Plaster has a significant curative effect in the treatment of hepatic fibrosis in chronic hepatitis B， which can improve the liver function of patients and effectively inhibit the progression of hepatic fibrosis.